Can-Fite says namodenoson improved decompensated cirrhosis outcomes
Can-Fite BioPharma reported patient resolution of ascites and regression of esophageal varices with namodenoson, with clinical stability for about 28 months before a successful liver transplantation.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.